LAUSR

“ Effect of HIPEC according to HRD/ BRCA wt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial. In our study, we performed post hoc exploratory analysis of the effect of cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC) on recurrence-free and overall survival in sub-groups defined according to the tumors' tumor profile ( BRCA1/2mut vs HRD /BRCAwt vs non-HRD /BRCA wt). Our study is the first to eval-uate the benefit of HIPEC according to the BRCA mutation status and homologous recombination deficiency (HRD) profiles in patients undergoing interval CRS, in a randomized phase III trial. We show that HIPEC may not add additional benefit over intravenously administered platinum for patients with BRCA1/2 m tumors and non-HRD/ BRCA wt tumors. Patients whose tumor harbor HRD /BRCAwt , how-ever, seem to experience most benefit on recurrence-free survival (RFS) and overall survival (OS) from the addition of HIPEC to interval cytoreductive surgery. We initially hypothesized that patients with HRD partial HR most likely to benefit treatment with HIPEC. al we our